JP6693745B2 - 抗ｃｄ４０抗体および使用方法 - Google Patents

抗ｃｄ４０抗体および使用方法 Download PDF

Info

Publication number
JP6693745B2
JP6693745B2 JP2015539949A JP2015539949A JP6693745B2 JP 6693745 B2 JP6693745 B2 JP 6693745B2 JP 2015539949 A JP2015539949 A JP 2015539949A JP 2015539949 A JP2015539949 A JP 2015539949A JP 6693745 B2 JP6693745 B2 JP 6693745B2
Authority
JP
Japan
Prior art keywords
antibody
seq
antigen
antibodies
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015539949A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015533853A5 (enExample
JP2015533853A (ja
Inventor
ヨンケ ジャン，
ヨンケ ジャン，
グオ−リャン ユウ，
グオ−リャン ユウ，
ウェイミン ズウ，
ウェイミン ズウ，
Original Assignee
アペクシジェン， インコーポレイテッド
アペクシジェン， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アペクシジェン， インコーポレイテッド, アペクシジェン， インコーポレイテッド filed Critical アペクシジェン， インコーポレイテッド
Publication of JP2015533853A publication Critical patent/JP2015533853A/ja
Publication of JP2015533853A5 publication Critical patent/JP2015533853A5/ja
Application granted granted Critical
Publication of JP6693745B2 publication Critical patent/JP6693745B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Physics & Mathematics (AREA)
JP2015539949A 2012-10-30 2013-10-30 抗ｃｄ４０抗体および使用方法 Active JP6693745B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261720289P 2012-10-30 2012-10-30
US61/720,289 2012-10-30
PCT/US2013/067583 WO2014070934A1 (en) 2012-10-30 2013-10-30 Anti-cd40 antibodies and methods of use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018147573A Division JP2018166522A (ja) 2012-10-30 2018-08-06 抗ｃｄ４０抗体および使用方法

Publications (3)

Publication Number Publication Date
JP2015533853A JP2015533853A (ja) 2015-11-26
JP2015533853A5 JP2015533853A5 (enExample) 2016-12-15
JP6693745B2 true JP6693745B2 (ja) 2020-05-13

Family

ID=49551838

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2015539949A Active JP6693745B2 (ja) 2012-10-30 2013-10-30 抗ｃｄ４０抗体および使用方法
JP2018147573A Withdrawn JP2018166522A (ja) 2012-10-30 2018-08-06 抗ｃｄ４０抗体および使用方法
JP2020139887A Withdrawn JP2020195388A (ja) 2012-10-30 2020-08-21 抗ｃｄ４０抗体および使用方法
JP2022163062A Active JP7482184B2 (ja) 2012-10-30 2022-10-11 抗ｃｄ４０抗体および使用方法
JP2024072388A Active JP7698352B2 (ja) 2012-10-30 2024-04-26 抗ｃｄ４０抗体および使用方法

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2018147573A Withdrawn JP2018166522A (ja) 2012-10-30 2018-08-06 抗ｃｄ４０抗体および使用方法
JP2020139887A Withdrawn JP2020195388A (ja) 2012-10-30 2020-08-21 抗ｃｄ４０抗体および使用方法
JP2022163062A Active JP7482184B2 (ja) 2012-10-30 2022-10-11 抗ｃｄ４０抗体および使用方法
JP2024072388A Active JP7698352B2 (ja) 2012-10-30 2024-04-26 抗ｃｄ４０抗体および使用方法

Country Status (11)

Country Link
US (5) US9676861B2 (enExample)
EP (2) EP2914627B1 (enExample)
JP (5) JP6693745B2 (enExample)
KR (1) KR102270618B1 (enExample)
CN (3) CN104918957B (enExample)
AU (2) AU2013337903B2 (enExample)
CA (1) CA2888763A1 (enExample)
DK (1) DK2914627T3 (enExample)
ES (1) ES2879552T3 (enExample)
NZ (1) NZ707086A (enExample)
WO (1) WO2014070934A1 (enExample)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2659517T3 (es) * 2007-05-30 2018-03-16 Xencor, Inc. Métodos y composiciones para inhibir células que expresan CD32B
CN102002104A (zh) 2009-08-28 2011-04-06 江苏先声药物研究有限公司 一种抗vegf的单克隆抗体及含有该抗体的药物组合物
US20140031250A1 (en) 2010-10-07 2014-01-30 David Tsai Ting Biomarkers of Cancer
AU2012249454B2 (en) 2011-04-29 2016-03-24 Apexigen, Inc. Anti-CD40 antibodies and methods of use
US9676861B2 (en) 2012-10-30 2017-06-13 Apexigen, Inc. Anti-CD40 antibodies and methods of use
EP3760208B1 (en) 2014-06-25 2024-05-29 The General Hospital Corporation Targeting human satellite ii (hsatii)
CN105693845B (zh) * 2014-11-24 2020-10-02 中国科学院上海营养与健康研究所 一种cd40胞外区的表达纯化及其用途
JP6518917B2 (ja) 2015-05-29 2019-05-29 アッヴィ・インコーポレイテッド 抗ｃｄ４０抗体およびその使用
AU2016291817A1 (en) 2015-07-16 2018-02-22 Biolinerx Ltd. Compositions and methods for treating cancer
EP3355921A4 (en) * 2015-09-30 2019-05-22 Janssen Biotech, Inc. ANTAGONIST ANTIBODIES SPECIFICALLY BINDING TO HUMAN CD40 AND METHODS OF USE
CA3004138A1 (en) 2015-11-03 2017-05-11 Janssen Biotech, Inc. Antibodies specifically binding pd-1 and tim-3 and their uses
CA3016534A1 (en) * 2016-03-04 2017-09-08 The Rockefeller University Antibodies to cd40 with enhanced agonist activity
AU2017252527A1 (en) * 2016-04-18 2018-11-08 Celldex Therapeutics, Inc. Agonistic antibodies that bind human CD40 and uses thereof
JP7178906B2 (ja) 2016-05-19 2022-11-28 ザ ジェネラル ホスピタル コーポレイション ナチュラルキラー細胞および制御性Ｔ細胞の活性を強化するためのプラットフォームである、その受容体ＩＬ－２Ｒβに繋ぎ止められたインターロイキン－２
US10519243B2 (en) * 2016-05-27 2019-12-31 Abbvie Biotherapeutics Inc. Anti-CD40 antibodies
BR112018074453A2 (pt) 2016-05-27 2019-03-19 Abbvie Biotherapeutics Inc. proteínas de ligação biespecíficas ligando uma protéina imunomoduladora e um antígeno tumoral
EP4371570A3 (en) 2016-06-08 2024-07-17 Xencor, Inc. Treatment of igg4-related diseases with anti-cd19 antibodies crossbinding to cd32b
JP2019528082A (ja) 2016-06-08 2019-10-10 シャンハイ ジャオ トン ユニバーシティ スクール オブ メディシン アゴニスト抗体の活性を増強する抗体重鎖定常領域配列
CA3026474A1 (en) 2016-06-20 2017-12-28 Kymab Limited Anti-pd-l1 and il-2 cytokines
WO2018011421A1 (en) 2016-07-14 2018-01-18 Genmab A/S Multispecific antibodies against cd40 and cd137
US10669344B2 (en) 2016-08-12 2020-06-02 Janssen Biotech, Inc. Engineered antibodies and other Fc-domain containing molecules with enhanced agonism and effector functions
SG11201900744SA (en) 2016-08-12 2019-02-27 Janssen Biotech Inc Fc engineered anti-tnfr superfamily member antibodies having enhanced agonistic activity and methods of using them
EP3534951A4 (en) * 2016-11-02 2020-09-23 Apexigen, Inc. ANTI-CD40 ANTIBODIES IN COMBINATION AND METHOD OF USES
US11471515B2 (en) 2016-11-09 2022-10-18 The Brigham And Women's Hospital, Inc. Restoration of tumor suppression using MRNA-based delivery system
JP2020511959A (ja) * 2017-03-29 2020-04-23 グリコトープ ゲーエムベーハー ヒト化抗ｃｄ４０抗体
TWI788340B (zh) * 2017-04-07 2023-01-01 美商必治妥美雅史谷比公司 抗icos促效劑抗體及其用途
EP3632932A4 (en) 2017-06-01 2021-08-18 Jiangsu Hengrui Medicine Co. Ltd. ANTI-CD40 ANTIBODIES, ANTIGEN BINDING FRAGMENT OF THIS ANTIGEN AND ASSOCIATED MEDICAL USE
WO2018233607A1 (en) * 2017-06-19 2018-12-27 Beijing Biocytogen Co., Ltd Genetically modified non-human animal with human or chimeric cd40
CN109136274B (zh) 2017-06-19 2021-04-23 百奥赛图江苏基因生物技术有限公司 人源化cd40基因改造动物模型的制备方法及应用
CN109384845B (zh) * 2017-08-14 2022-06-21 中国科学院上海营养与健康研究所 一种cd40单克隆抗体、其制备方法及其应用
WO2019143837A1 (en) 2018-01-17 2019-07-25 Apexigen, Inc. Anti-pd-l1 antibodies and methods of use
US12398209B2 (en) 2018-01-22 2025-08-26 Janssen Biotech, Inc. Methods of treating cancers with antagonistic anti-PD-1 antibodies
EP4317972A3 (en) 2018-02-06 2024-03-13 The General Hospital Corporation Repeat rna as biomarkers of tumor immune response
CA3097007A1 (en) * 2018-04-20 2019-10-24 Lyvgen Biopharma Co., Ltd. Anti-cd40 antibodies and uses thereof
AU2019287765A1 (en) 2018-06-15 2021-01-07 Flagship Pioneering Innovations V, Inc. Increasing immune activity through modulation of postcellular signaling factors
CN120843603A (zh) 2018-07-11 2025-10-28 布里格姆妇女医院 用于跨血脑屏障递送试剂的方法和组合物
CN112566933B (zh) 2018-07-20 2023-07-14 祐和医药科技(北京)有限公司 抗cd40抗体及其用途
AR117091A1 (es) 2018-11-19 2021-07-07 Bristol Myers Squibb Co Anticuerpos monoclonales antagonistas contra cd40 y sus usos
JP7515475B2 (ja) 2018-11-23 2024-07-12 ストライク ファーマ アクティエボラーグ 二重特異性コンジュゲート
TW202039558A (zh) 2018-11-30 2020-11-01 大陸商江蘇恆瑞醫藥股份有限公司 抗ｃｄ４０抗體、其抗原結合片段及其醫藥用途
KR20210097750A (ko) 2018-11-30 2021-08-09 지앙수 헨그루이 메디슨 컴퍼니 리미티드 Cd40 항체 약학 조성물 및 이의 용도
CN109678959B (zh) * 2019-02-22 2020-12-08 北京免疫方舟医药科技有限公司 抗cd40抗体及其应用
US10570210B1 (en) 2019-03-04 2020-02-25 Beijing Mabworks Biotech Co.Ltd Antibodies binding CD40 and uses thereof
CN111454363B (zh) * 2019-03-04 2021-03-02 北京天广实生物技术股份有限公司 Cd40抗体及其用途
EP3947640A4 (en) 2019-04-02 2022-12-14 The Brigham & Women's Hospital, Inc. PROCEDURE FOR DETERMINING THE PROGRESSION OF PRIMARY MELANOMA
AU2020256828A1 (en) 2019-04-10 2021-11-18 Nankai University Anti-CD40 antibody and use thereof
MA55805A (fr) 2019-05-03 2022-03-09 Flagship Pioneering Innovations V Inc Métodes de modulation de l'activité immunitaire
WO2021048135A1 (en) 2019-09-09 2021-03-18 Basilea Pharmaceutica International AG Pharmaceutical combinations comprising a furazanobenzimidazoles and a cd40 agonist for use in the treatment of neoplastic diseases
WO2021048595A1 (en) * 2019-09-11 2021-03-18 Novartis Ag A method for preventing human virus associated disorders in patients
CN116057070A (zh) * 2019-10-23 2023-05-02 礼进生物医药科技（上海）有限公司 抗cd40结合分子和包括其的双特异性抗体
EP4076434A1 (en) 2019-12-17 2022-10-26 Flagship Pioneering Innovations V, Inc. Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly
WO2021142300A2 (en) 2020-01-10 2021-07-15 The Brigham And Women's Hospital, Inc. Methods and compositions for delivery of immunotherapy agents across the blood-brain barrier to treat brain cancer
GB202008003D0 (en) 2020-05-28 2020-07-15 Quine Medical Ab Anti-CD40 antibody
CA3184366A1 (en) 2020-06-29 2022-01-06 Darby Rye Schmidt Viruses engineered to promote thanotransmission and their use in treating cancer
WO2022002065A1 (zh) * 2020-06-30 2022-01-06 百奥泰生物制药股份有限公司 抗cd40抗体或抗原结合片段及其应用
JP2024512669A (ja) 2021-03-31 2024-03-19 フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド タノトランスミッションポリペプチド及び癌の処置におけるそれらの使用
AU2022303363A1 (en) 2021-06-29 2024-01-18 Flagship Pioneering Innovations V, Inc. Immune cells engineered to promote thanotransmission and uses thereof
US20240398942A1 (en) * 2021-09-26 2024-12-05 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Use of anti-cd40 antibody
US20250376533A1 (en) 2022-05-31 2025-12-11 Futuregen Biopharmaceutical (Beijing) Co., Ltd. Anti-cd40 antibody, anti-pd-l1×cd40 bispecific antibody, and use thereof
EP4598946A1 (en) 2022-10-05 2025-08-13 Flagship Pioneering Innovations V, Inc. Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer
US20240269251A1 (en) 2023-01-09 2024-08-15 Flagship Pioneering Innovations V, Inc. Genetic switches and their use in treating cancer
CN120659814A (zh) 2023-02-13 2025-09-16 浙江大学绍兴研究院 双特异性抗体及其应用
WO2025061682A1 (en) 2023-09-21 2025-03-27 Universität Zürich Adenoviral targeting of dendritic cells

Family Cites Families (114)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3896111A (en) 1973-02-20 1975-07-22 Research Corp Ansa macrolides
US4237224A (en) 1974-11-04 1980-12-02 Board Of Trustees Of The Leland Stanford Jr. University Process for producing biologically functional molecular chimeras
US4151042A (en) 1977-03-31 1979-04-24 Takeda Chemical Industries, Ltd. Method for producing maytansinol and its derivatives
US4137230A (en) 1977-11-14 1979-01-30 Takeda Chemical Industries, Ltd. Method for the production of maytansinoids
US4307016A (en) 1978-03-24 1981-12-22 Takeda Chemical Industries, Ltd. Demethyl maytansinoids
US4265814A (en) 1978-03-24 1981-05-05 Takeda Chemical Industries Matansinol 3-n-hexadecanoate
JPS5562090A (en) 1978-10-27 1980-05-10 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
US4256746A (en) 1978-11-14 1981-03-17 Takeda Chemical Industries Dechloromaytansinoids, their pharmaceutical compositions and method of use
JPS55164687A (en) 1979-06-11 1980-12-22 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS5566585A (en) 1978-11-14 1980-05-20 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS55102583A (en) 1979-01-31 1980-08-05 Takeda Chem Ind Ltd 20-acyloxy-20-demethylmaytansinoid compound
JPS55162791A (en) 1979-06-05 1980-12-18 Takeda Chem Ind Ltd Antibiotic c-15003pnd and its preparation
JPS55164685A (en) 1979-06-08 1980-12-22 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS55164686A (en) 1979-06-11 1980-12-22 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
US4309428A (en) 1979-07-30 1982-01-05 Takeda Chemical Industries, Ltd. Maytansinoids
JPS5645483A (en) 1979-09-19 1981-04-25 Takeda Chem Ind Ltd C-15003phm and its preparation
JPS5645485A (en) 1979-09-21 1981-04-25 Takeda Chem Ind Ltd Production of c-15003pnd
EP0028683A1 (en) 1979-09-21 1981-05-20 Takeda Chemical Industries, Ltd. Antibiotic C-15003 PHO and production thereof
WO1981001145A1 (en) 1979-10-18 1981-04-30 Univ Illinois Hydrolytic enzyme-activatible pro-drugs
WO1982001188A1 (en) 1980-10-08 1982-04-15 Takeda Chemical Industries Ltd 4,5-deoxymaytansinoide compounds and process for preparing same
US4450254A (en) 1980-11-03 1984-05-22 Standard Oil Company Impact improvement of high nitrile resins
US4313946A (en) 1981-01-27 1982-02-02 The United States Of America As Represented By The Secretary Of Agriculture Chemotherapeutically active maytansinoids from Trewia nudiflora
US4315929A (en) 1981-01-27 1982-02-16 The United States Of America As Represented By The Secretary Of Agriculture Method of controlling the European corn borer with trewiasine
JPS57192389A (en) 1981-05-20 1982-11-26 Takeda Chem Ind Ltd Novel maytansinoid
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US5247069A (en) 1986-06-13 1993-09-21 Oncogen Ligands and methods for augmenting B-cell proliferation
US5182368A (en) * 1986-06-13 1993-01-26 Ledbetter Jeffrey A Ligands and methods for augmenting B-cell proliferation
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
GB8705477D0 (en) 1987-03-09 1987-04-15 Carlton Med Prod Drug delivery systems
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US4975278A (en) 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
CA2026147C (en) 1989-10-25 2006-02-07 Ravi J. Chari Cytotoxic agents comprising maytansinoids and their therapeutic use
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5151510A (en) 1990-04-20 1992-09-29 Applied Biosystems, Inc. Method of synethesizing sulfurized oligonucleotide analogs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5264586A (en) 1991-07-17 1993-11-23 The Scripps Research Institute Analogs of calicheamicin gamma1I, method of making and using the same
ZA932522B (en) 1992-04-10 1993-12-20 Res Dev Foundation Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
US5397703A (en) 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
US6765087B1 (en) 1992-08-21 2004-07-20 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
ATE199392T1 (de) 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
ATE204325T1 (de) 1993-04-29 2001-09-15 Unilever Nv Herstellung von antikörpern oder funktionstüchtig gemachten teilen davon, abgeleitet von schweren ketten von immunglobulinen von camelidae
PT724456E (pt) 1993-10-01 2004-04-30 Immunex Corp Anticorpos contra cd4
DE69433820T2 (de) 1993-12-23 2005-06-23 Immunex Corp., Seattle Verwendung von löslichen oligomerischen cd40 liganden oder monoklonalen antikörpern zur herstellung eines arzneimitells zur vorbeugung oder behandlung von neoplastischen krankheiten
US5837458A (en) 1994-02-17 1998-11-17 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
GB9425060D0 (en) 1994-12-13 1995-02-08 Univ Birmingham Carcinoma treatment
US5675063A (en) 1995-02-28 1997-10-07 Loyola University Of Chicago Immortalized rabbit hybridoma fusion partner
JP3657271B2 (ja) 1995-03-01 2005-06-08 イミュネックス・コーポレーション 病原性または日和見感染性生物に感染した哺乳動物の治療のための組成物
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US5712374A (en) 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
EP1033406A4 (en) * 1997-10-27 2005-03-09 Sumitomo Electric Industries INDUCER FOR THE PRODUCTION OF ANTIGEN-SPECIFIC ANTIBODY, EXPRESSION VECTOR CONTAINING THE GENE REQUIRED THEREFOR, AND METHOD FOR INDUCING THE PRODUCTION OF THE ANTIGEN-SPECIFIC ANTIBODY
US6051228A (en) 1998-02-19 2000-04-18 Bristol-Myers Squibb Co. Antibodies against human CD40
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
KR100301796B1 (ko) * 1998-10-01 2001-09-06 성재갑 면역억제능이 있는 항-씨디40 리간드 모노클로날 항체
US6680176B2 (en) 1999-05-17 2004-01-20 The United States Of America, As Represented By The Department Of Health And Human Services Identification of candidate ligands which modulate antigen presenting cells
US20030118588A1 (en) 1999-05-22 2003-06-26 Linda Diehl Induction of anti-tumor CTL immunity through in vivo triggering of 4-1BB and/or CD40
US6946129B1 (en) 1999-06-08 2005-09-20 Seattle Genetics, Inc. Recombinant anti-CD40 antibody and uses thereof
JP2003524644A (ja) 2000-02-01 2003-08-19 タノックス インコーポレイテッド Ｃｄ４０−結合性ａｐｃ−活性化分子
CN1450912A (zh) 2000-04-19 2003-10-22 泰诺士公司 用于治疗牛皮癣和其它炎性皮肤病的cd40拮抗剂
US7063845B2 (en) 2000-04-28 2006-06-20 Gemini Science, Inc. Human anti-CD40 antibodies
KR100881471B1 (ko) 2000-05-08 2009-02-05 셀덱스 쎄라퓨틱스, 인크. 수상세포에 대한 인간 모노클로날 항체
ATE374214T1 (de) 2001-04-27 2007-10-15 Kirin Brewery Monoklonaler anti-cd-40-antikörper
JP4025881B2 (ja) * 2001-04-27 2007-12-26 キリンファーマ株式会社 抗ｃｄ４０モノクローナル抗体
AR039067A1 (es) * 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
US20080199471A1 (en) 2002-03-01 2008-08-21 Bernett Matthew J Optimized cd40 antibodies and methods of using the same
AU2003217912A1 (en) * 2002-03-01 2003-09-16 Xencor Antibody optimization
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US7662925B2 (en) 2002-03-01 2010-02-16 Xencor, Inc. Optimized Fc variants and methods for their generation
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
WO2004063351A2 (en) 2003-01-09 2004-07-29 Macrogenics, Inc. IDENTIFICATION AND ENGINEERING OF ANTIBODIES WITH VARIANT Fc REGIONS AND METHODS OF USING SAME
US7960512B2 (en) 2003-01-09 2011-06-14 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
ES2349777T3 (es) * 2003-01-22 2011-01-11 Glycart Biotechnology Ag Constructos de fusión y uso de los mismos para producir anticuerpos con mayor afinidad de unión al receptor de fc y función efectora.
EP2248830A1 (en) * 2003-11-04 2010-11-10 Novartis Vaccines and Diagnostics, Inc. Use of antagonist anti-CD40 antibodies for treatment of autoimmune and inflammatory diseases and organ transplant rejection
EP2221315A1 (en) 2003-12-04 2010-08-25 Xencor, Inc. Methods of generating variant proteins with increased host string content and compositions thereof
US20050136055A1 (en) 2003-12-22 2005-06-23 Pfizer Inc CD40 antibody formulation and methods
KR101200188B1 (ko) * 2003-12-25 2012-11-13 교와 핫꼬 기린 가부시키가이샤 항 ｃｄ４０ 항체의 변이체
PL1776384T3 (pl) 2004-08-04 2013-10-31 Mentrik Biotech Llc WARIANTY REGIONÓW Fc
US7462697B2 (en) 2004-11-08 2008-12-09 Epitomics, Inc. Methods for antibody engineering
US7632497B2 (en) 2004-11-10 2009-12-15 Macrogenics, Inc. Engineering Fc Antibody regions to confer effector function
EP1844073A1 (en) 2005-01-31 2007-10-17 Ablynx N.V. Method for generating variable domain sequences of heavy chain antibodies
US20060257359A1 (en) 2005-02-28 2006-11-16 Cedric Francois Modifying macrophage phenotype for treatment of disease
AU2006230413B8 (en) 2005-03-31 2011-01-20 Xencor, Inc Fc variants with optimized properties
WO2006125143A2 (en) 2005-05-18 2006-11-23 Novartis Ag Methods for diagnosis and treatment of proliferative disorders mediated by cd40 signaling
HRP20130852T1 (en) 2005-05-18 2013-10-25 Novartis Ag Methods for diagnosis and treatment of diseases having an autoimmune and/or inflammatory component
ES2354865T3 (es) 2005-05-26 2011-03-18 Seattle Genetics, Inc. Anticuerpos anti-cd40 humanizados y métodos para utilizarlos.
US7429487B2 (en) 2005-07-05 2008-09-30 Epitomics, Inc. Fusion partner for production of monoclonal rabbit antibodies
JP2009517339A (ja) * 2005-11-01 2009-04-30 ノバルティス アーゲー 抗ｃｄ４０抗体の使用
CN101351478A (zh) 2005-11-01 2009-01-21 诺华有限公司 抗cd40抗体的应用
KR101866623B1 (ko) 2005-11-28 2018-07-04 젠맵 에이/에스 재조합 １가 항체 및 그의 제조 방법
WO2007075326A2 (en) 2005-12-09 2007-07-05 Seattle Genetics, Inc. Methods of using cd40 binding agents
CA2669412A1 (en) * 2007-01-23 2008-07-31 Xencor, Inc. Optimized cd40 antibodies and methods of using the same
US8062864B2 (en) 2007-05-21 2011-11-22 Alderbio Holdings Llc Nucleic acids encoding antibodies to IL-6, and recombinant production of anti-IL-6 antibodies
KR20100028571A (ko) 2007-05-21 2010-03-12 앨더 바이오파마슈티컬즈, 인코포레이티드 신규한 래빗 항체 인간화 방법 및 인간화된 래빗 항체
US20090238825A1 (en) 2007-05-21 2009-09-24 Kovacevich Brian R Novel rabbit antibody humanization methods and humanized rabbit antibodies
ES2659517T3 (es) 2007-05-30 2018-03-16 Xencor, Inc. Métodos y composiciones para inhibir células que expresan CD32B
AU2009206506B2 (en) 2008-01-23 2013-01-10 Xencor, Inc. Optimized CD40 antibodies and methods of using the same
ES2890230T3 (es) 2008-07-16 2022-01-18 Baylor Res Institute Vacuna contra el VIH basada en el direccionamiento de Gag y Nef maximizado a células dendríticas
US20110311525A1 (en) 2008-08-29 2011-12-22 Academisch Ziekenhuis Leiden H.O.D.N. Lumc Delivery of a cd40 agonist to a tumor draining lymph node of a subject
US8435514B2 (en) 2008-12-05 2013-05-07 Als Therapy Development Institute Method for the treatment of neurodegenerative diseases
PT2406286T (pt) 2009-03-10 2016-08-19 Baylor Res Inst Anticorpos anti-cd40 e seus usos
BRPI1011394A8 (pt) 2009-04-18 2018-06-26 Genentech Inc método para avaliação de responsividade de linforma de células b ao tratamento com anticorpos anti-cd40
ES2829423T3 (es) 2009-04-20 2021-05-31 Kyowa Kirin Co Ltd Anticuerpo anti-CD40 que contiene IgG2 que presenta tres mutaciones de aminoácido introducidas en el mismo
BR112012024489A2 (pt) * 2010-03-29 2016-05-31 Zymeworks Inc anticorpos com função efetora suprimida ou aumentada
RS57114B1 (sr) 2010-03-31 2018-06-29 Boehringer Ingelheim Int Anti-cd40 antitela
US10131875B2 (en) 2010-08-04 2018-11-20 Duke University Regulatory B cells and their uses
AR083847A1 (es) 2010-11-15 2013-03-27 Novartis Ag Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40
CA3167037A1 (en) 2010-12-20 2012-06-28 The Rockefeller University Modulating agonistic tnfr antibodies
EP2699601B1 (en) * 2011-04-21 2018-01-17 Bristol-Myers Squibb Company Antibody polypeptides that antagonize cd40
AU2012249454B2 (en) 2011-04-29 2016-03-24 Apexigen, Inc. Anti-CD40 antibodies and methods of use
US9676861B2 (en) 2012-10-30 2017-06-13 Apexigen, Inc. Anti-CD40 antibodies and methods of use
US9209965B2 (en) 2014-01-14 2015-12-08 Microsemi Semiconductor Ulc Network interface with clock recovery module on line card

Also Published As

Publication number Publication date
AU2018256638B2 (en) 2020-09-10
NZ707086A (en) 2019-07-26
US20230406948A1 (en) 2023-12-21
JP7482184B2 (ja) 2024-05-13
CA2888763A1 (en) 2014-05-08
HK1213581A1 (zh) 2016-07-08
DK2914627T3 (da) 2021-07-12
US20170246297A1 (en) 2017-08-31
US9994640B2 (en) 2018-06-12
EP2914627B1 (en) 2021-04-07
US20180273630A1 (en) 2018-09-27
JP2022191360A (ja) 2022-12-27
JP2024096245A (ja) 2024-07-12
US20140120103A1 (en) 2014-05-01
EP3925977A1 (en) 2021-12-22
JP2020195388A (ja) 2020-12-10
US9676861B2 (en) 2017-06-13
AU2013337903A1 (en) 2015-05-07
CN110066335B (zh) 2024-04-05
EP2914627A1 (en) 2015-09-09
US20220049006A1 (en) 2022-02-17
AU2018256638A1 (en) 2018-11-29
KR20150079787A (ko) 2015-07-08
AU2013337903B2 (en) 2018-08-16
JP2015533853A (ja) 2015-11-26
KR102270618B1 (ko) 2021-06-30
JP7698352B2 (ja) 2025-06-25
CN104918957B (zh) 2018-11-16
CN104918957A (zh) 2015-09-16
CN109265552A (zh) 2019-01-25
WO2014070934A1 (en) 2014-05-08
CN110066335A (zh) 2019-07-30
ES2879552T3 (es) 2021-11-22
JP2018166522A (ja) 2018-11-01

Similar Documents

Publication Publication Date Title
JP7482184B2 (ja) 抗ｃｄ４０抗体および使用方法
US20240158523A1 (en) Anti-cd40 antibodies and methods of use
JP2014515612A5 (enExample)
HK40068031A (en) Anti-cd40 antibodies and methods of use
HK40011413A (en) Anti-cd40 antibodies and methods of use
HK1240603B (zh) 抗-cd40抗体及其使用方法
NZ616923B2 (en) Anti-cd40 antibodies and methods of use
HK1213581B (en) Anti-cd40 antibodies and methods of use

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161025

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20161025

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20170809

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170817

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20171115

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171213

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20180426

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180806

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20180814

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20180928

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20191101

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191226

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200127

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200416

R150 Certificate of patent or registration of utility model

Ref document number: 6693745

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250